|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
Print
October 20, 2017 07:30 ET | Source: Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine phenylacetate) in development for the treatment and prevention of hepatic encephalopathy (HE) will be presented at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 20-24, 2017, at the Washington Convention Center in Washington, D.C. Select findings from each presentation are cited below.
Poster Presentations:
Session: Complications of Cirrhosis I
Session Date and Time: October 20, 2017 from 8:00 AM to 5:30 PM ET
Location: Hall D
“STOP-HE: A Randomized, Double-blind, Placebo-controlled Study of OCR-002 in Patients with Hepatic Encephalopathy” - Publication Number: 502; Select findings include:
The study demonstrated that OCR-002 reduced time to improvement in cirrhotic patients hospitalized with HE and elevated baseline ammonia, compared to placebo + standard of care (SOC) (p=0.034).
The study confirmed the mechanism of action (MOA) of OCR-002 as an ammonia scavenger.
Patients on OCR-002 normalized their ammonia faster than patients on placebo, which correlated with faster clinical improvement.
The data support further study of OCR-002 as a new treatment option for patients hospitalized with overt HE.
“Geographic Differences for Patients Enrolled in STOP-HE: A Randomized, Phase 2 Study of OCR-002 for Hepatic Encephalopathy” - Publication Number: 499; Select findings include:
In STOP-HE, differences were observed between patients enrolled in North America and Rest of World for baseline characteristics, severity of liver disease, use of concomitant medications and use of SOC treatments.
Further study is needed to explore these differences more thoroughly.
Geographic differences should be considered when designing clinical trials in patients with HE in order to avoid any bias.
“An Open-Label Crossover Study of the Pharmacokinetics of Ornithine Phenylacetate (OCR-002) after IV and Oral Doses in Subjects with Cirrhosis” - Publication Number: 501; Select findings include:
Phenylacetate was rapidly absorbed and almost completely bioavailable (≥95%) from oral doses of OCR-002 in subjects with cirrhosis.
Single oral and intravenous doses of 5g OCR-002 are well tolerated in cirrhotic subjects with Child Pugh A and C classification1.
The prolonged plasma half-life of PAA in cirrhotic subjects may allow reduced dosing frequency of oral OCR-002.
Results of this study support the rationale for the development of an oral formulation of OCR-002 for reducing ammonia levels in cirrhotic patients.
Oral Presentation:
Parallel 33: Portal Hypertension: Risk Assessment and Treatment
Session Date and Time: October 23, 2017 from 3:00 PM to 4:30 PM ET
Presentation Time: 3:30 PM to 3:45 PM ET
Location: Room 207
“OCR-002 (Ornithine Phenylacetate) is a Potent Ammonia Scavenger as Demonstrated in Phase 2b STOP-HE Study” - Publication Number: 219; Select findings include:
Findings from STOP-HE confirm the MOA of OCR-002 as a potent ammonia scavenger.
OCR-002 use in cirrhotic patients hospitalized with HE reduced plasma ammonia levels to a greater extent than placebo and SOC.
OCR-002 reduced ammonia levels faster than placebo and SOC.
OCR-002 led to faster clinical improvement than placebo and SOC.
Results from this study will be used for study design for continued OCR-002 development.
“We are very pleased to have several presentations at AASLD highlighting the potential for OCR-002,” said Linda Grais, M.D., CEO of Ocera. “We look forward to the data from our oral Phase 2a study later this year and to advancing the i.v. program following our upcoming meetings with the FDA.”
“OCR-002 holds the promise for these acutely ill patients for which there is no direct ammonia scavenger approved by the FDA to treat them,” said Professor Rajiv Jalan, M.B.B.S, M.D. Ph.D. “In a recent study conducted by my team evaluating cirrhotic patients with acute decompensation, we found that elevated ammonia left unchecked or allowed to rise is not only correlated with HE severity but is an independent predictor of mortality2.”
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (i.v.) and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and a
cute-on-chronic liver disease.
Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with FDA later this year to review the i.v. program and discuss potential development paths forward.
Ocera is currently evaluating its oral tablet form of OCR-002 in a Phase 2a study in patients with cirrhosis as a chronic use option to maintain remission of HE. Results of this study are expected to be published by the end of 2017. For additional information, please see www.ocerainc.com.
|
|
发表于 2017-10-22 16:15